Severe community-acquired pneumonia (sCAP) is a major global health challenge, with high morbidity and mortality, especially ...

Objectives Infliximab, an anti-TNF agent, is used to treat sarcoidosis that does not respond to corticosteroids or second-line agents. The efficacy of other anti-TNF agents, non-TNF biologics and ...

1 Laboratory of Allergology and Pulmonary Diseases, Department of Pathology and Medical Biology, University Medical Center Groningen, GRIAC Research Institute, University of Groningen, Groningen, The ...

The BTS/SIGN/NICE have recently published updated guidance for the treatment of asthma.1 The guideline advises that inhaler choice should be based on the lowest environmental impact among suitable ...

Introduction Tocilizumab improves outcomes in critically ill patients with COVID-19. Whether other immune-modulator strategies are equally effective or better is unknown. Methods We investigated ...

Oxford Children's Hospital, The John Radcliffe, Headington, Oxford, UK Correspondence to Dr Anne Thomson, Oxford Children's Hospital, The John Radcliffe, Headley Way, Headington, Oxford OX3 9DU, UK; ...

BACKGROUND The potential for long term adverse effects from inhaled corticosteroids relates to their systemic absorption, usually assessed from proxy markers in short term studies. When fluticasone ...

Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators ...

Respiratory Department of Hospital Universitari de Bellvitge, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain ...

Clinical Research Unit at the Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany Professor R Bals, Department of Internal Medicine, Division of Pulmonology, ...

17 Academic Respiratory Unit, Bristol Medical School, University of Bristol, Bristol, UK Correspondence to Professor Nick A Maskell, Academic Respiratory Unit, Bristol Medical School, University of ...

BACKGROUND Patients with cystic fibrosis (CF) have many risk factors for reduced bone mineral density (BMD). The aim of this study was to determine the prevalence of osteoporosis and osteopenia in a ...